Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...

AI is reshaping labs and Clever Culture’s tech is gaining Big Pharma attention as diagnostics and cleanrooms go digital. Step ...

The administration of US President Donald Trump has taken a series of actions since January, 2025 that directly threaten the ...

Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 ...

India’s offer comes in the backdrop of the US administration’s stated desire to sharply reduce local drug prices, and gains ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs; The agreement includes pr ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out ...

Amid renewed tariff threats and Treasury market volatility, global markets have seen a downturn, with small- and mid-cap indexes suffering the most significant declines. As investors navigate these ...

LIC Mutual Fund's Dikshit Mittal suggests focusing on companies catering to the upper-middle class and affluent Indian ...

As many of you have heard me say in the past, computational and AI-driven approaches are increasing their presence and usage at both large and emerging pharma companies for all facets of drug ...

Sun Pharma is making tactical moves to reinforce its leadership in specialty pharmaceuticals while accelerating global expansion. On March 10, it announced the acquisition of Nasdaq-listed ...